Skip to main content
OpenTrials
Completed

NCT Number: NCT01867008

Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults

Clinical study to evaluate the safety and efficacy of the Cochlear™ Nucleus® CI422 cochlear implant for new cochlear implant adult recipients with broader requirements to be considered an eligible candidate.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Greater Baltimore Medical Center, Baltimore, Maryland, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eighteen years of age or older at the time of implantation
  • Moderate low frequency thresholds up to and including 1000 Hz, severe to profound high frequency (above 3000 Hz) sensorineural hearing loss
  • Minimum of 30 days experience with appropriately fit bilateral amplification, fit using the standardized National Acoustics Laboratory (NAL) fitting method described in the Fitting and Use of Hearing Aids section below
  • Aided Consonant Nucleus Consonant (CNC) word recognition score (mean of two lists) between 10% and 50%, inclusive in the ear to be implanted
  • Aided CNC word recognition score (mean of two lists) in the contralateral ear equal to, or better than, the ear to be implanted but not more than 70%
  • Willingness to use bimodal stimulation (i.e., a cochlear implant on one ear and a hearing aid on the contralateral ear) through at least 6-months postactivation
  • English spoken as a primary language

Exclusion criteria

  • Duration of severe-to-profound hearing loss greater than 30 years
  • Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age)
  • Medical or psychological conditions that contraindicate undergoing surgery as determined by the Investigator
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array
  • Conductive overlay of 15 decibels (dB) or greater at two or more frequencies, in the range 500 to 1000 Hz
  • Deafness due to lesions of the acoustic nerve or central auditory pathway
  • Absence of cochlear development
  • Diagnosis of auditory neuropathy
  • Active middle-ear infection
  • Tympanic membrane perforation in the presence of active middle ear disease
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
  • Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator
  • Additional handicaps that would prevent or restrict participation in the audiological evaluations as determined by the Investigator

Treatment and study plan

Nucleus CI422 Cochlear Implant with N6 Sound Processor

Device

Primary outcomes

  1. Change in Open Set Monosyllabic Word Recognition Score as Measured on a Consonant Nucleus Consonant (CNC) Word Test

    Time frame: Preoperative baseline to 6 months postactivation

    Performance at 6 months postactivation compared to pre-operative word recognition score (percent correct: 0-100%, where a 0% is the lowest score and a 100% is the highest score)

Sponsors and collaborators

Lead sponsor

Cochlear

Industry

Registry information

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Jun 3, 2013
Registry last updated
Jan 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.